Roche today reported a 7 percent increase in molecular diagnostics sales for the first nine months of 2015, driven by virology testing, HPV screening, and noninvasive prenatal testing.

Overall, the company booked CHF 35.53 billion ($36.57 billion) in sales for the period, a two percent increase over the CHF 34.76 billion in sales for the same period last year.

The diagnostics division had sales of CHF 7.84 billion for the first three quarters, up 1 percent over last year's CHF 7.79 billion. At constant exchange rates, diagnostics sales were up 6 percent, and the division continues to see "very good momentum," Roland Diggelmann, COO of Roche Diagnostics, said in a conference call to discuss the earnings.

Molecular diagnostics sales, which accounted for 16 percent of all diagnostics sales, grew 7 percent to CHF 1.25 billion. At constant exchange rates, the increase was 10 percent.